Does a 3mm lesion anterior to the psoas, caudal to the lower pole of the left kidney, present since 1.5 months post-partial nephrectomy for stage T1a low-grade Chromophobe Renal Cell Carcinoma (RCC), represent a malignant or benign process?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

This lesion most likely represents a benign process rather than a malignant one, given its small size, stability over time, and the fact that it was present shortly after partial nephrectomy. The patient's history of stage T1a low-grade Chromophobe Renal Cell Carcinoma (RCC) and the presence of a 3mm lesion anterior to the psoas, caudal to the lower pole of the left kidney, 1.5 months post-partial nephrectomy, suggests a low risk of malignancy. According to the American College of Radiology Appropriateness Criteria 1, for low-risk/T1 tumors, abdominal imaging is recommended, but the small size and stability of the lesion are reassuring features.

  • The lesion's characteristics, such as its small size (3mm) and stability over time, are more consistent with a benign process, such as post-surgical changes, scarring, or a small benign nodule in the retroperitoneal fat.
  • Malignant lesions, particularly metastases, typically demonstrate more substantial growth over a similar timeframe 1.
  • The American Society of Clinical Oncology clinical practice guideline 1 suggests that small renal masses (SRMs) are often benign or indolent, and that imaging modalities cannot reliably discriminate between malignant and benign SRMs.
  • Given the low risk of malignancy and the potential for benignity, continued surveillance imaging is still recommended to monitor this lesion, even though its characteristics strongly suggest it is benign 1.
  • If there are concerns, a multidisciplinary discussion with urology and radiology might be beneficial to determine if any additional workup is necessary.

From the Research

Lesion Characteristics

  • The lesion is 3mm in size and located anterior to the psoas, caudal to the lower pole of the left kidney.
  • It has been present for 1.5 months post-partial nephrectomy for stage T1a low-grade Chromophobe Renal Cell Carcinoma (RCC).

Possible Causes

  • The lesion could be a malignant process, potentially a recurrence of the Chromophobe Renal Cell Carcinoma 2, 3.
  • It could also be a benign process, such as a cyst or a non-neoplastic lesion 4, 5.

Chromophobe Renal Cell Carcinoma

  • Chromophobe Renal Cell Carcinoma is a rare subtype of renal cell carcinoma, accounting for 4-6% of renal cell carcinoma subtypes 2.
  • It generally has a good prognosis, but can occasionally exhibit aggressive behavior, such as retrograde venous invasion and gain of chromosome 21 3.
  • Immunohistochemical studies have shown that chromophobe renal cell carcinoma is positive for epithelial membrane antigen and E-cadherin, but negative for vimentin and N-cadherin 5.

Nephron-Sparing Surgery

  • Nephron-sparing surgery (NSS) is a safe and effective method for treating carefully selected renal cell carcinoma patients, including those with chromophobe renal cell carcinoma 6.
  • The study found that NSS can be performed with minimal complications and low recurrence rates, making it a viable option for patients with small renal tumors 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Chromophobe renal cell carcinoma: an immunohistochemical study of 21 Japanese cases.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 1999

Research

[Application of nephron-sparing surgery in the treatment of renal cell carcinoma].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2009

Related Questions

Does a 3mm lesion anterior to the psoas, caudal to the lower pole of the left kidney, present since 1.5 months post-partial nephrectomy for stage T1a low-grade Chromophobe Renal Cell Carcinoma (RCC), represent a malignant or benign process?
What is the significance of a 3 mm nodule near the left kidney in a patient with a history of partial nephrectomy for Chromophobe renal cell carcinoma (RCC)?
Is a 3 mm nodule appearing 1 month after partial nephrectomy for T1a chromophobe (renal cell carcinoma) located in the fat anterior to the psoas muscle below the lower pole of the kidney scar tissue?
What is the significance of a 3 mm nodule in the fat anterior to the psoas muscle, present one month post-partial nephrectomy for chromophobe Renal Cell Carcinoma (RCC) and persisting over three years?
What is the significance of a 1.5 cm mass in the perinephric space adjacent to the surgical bed, 3 years after partial nephrectomy for a 1.3 cm chromophobe renal cell carcinoma (RCC) T1a?
What is the relationship between oral narcotics (opioids) and hypotension?
Does a 3mm lesion anterior to the psoas, caudal to the lower pole of the left kidney, present since 1.5 months post-partial nephrectomy for Stage 1 Chromophobe Renal Cell Carcinoma (RCC), most likely represent a malignant or benign process?
What is the post-ingestion dietary protocol after capsule endoscopy?
What electrocardiogram (ECG) abnormalities are expected during an acute cerebrovascular accident (CVA)?
What is the indication for a resuscitative thoracotomy (emergency thoracotomy)?
What is the differential diagnosis for a patient who experiences syncope (fainting) while eating?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.